CYTK (US) share price forecast & AI signal — Cytokinetics, Incorporated
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in CYTK
Cytokinetics, Incorporated is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral,...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $53.69 |
| 2026-11-05 | $55.55 |
| 2026-11-04 | $63.60 |
| 2026-11-03 | $62.31 |
| 2026-11-02 | $62.03 |
| 2026-10-30 | $62.99 |
| 2026-10-29 | $63.31 |
CYTK FAQ
Is Cytokinetics, Incorporated (CYTK) a buy or sell this week?
The ACE Stock Bots machine-learning model rates CYTK a SELL for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for CYTK?
Every week the model scores CYTK across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.